Parvovirus B19 empty capsids as antigen carriers for presentation of antigenic determinants of dengue 2 virus

Journal of Infectious Diseases

Volumn 194, Issue 6, 2006, Pages 790-794

  Amexis, Georgios ^a   Young, Neal S ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; ANTIGEN; DENGUE VACCINE; ENVELOPE PROTEIN; EPITOPE; FREUND ADJUVANT; GLYCOPROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY TITER; ANTIGEN PRESENTATION; ANTIGEN SPECIFICITY; ARTICLE; CONTROLLED STUDY; DENGUE VIRUS; HUMORAL IMMUNITY; MOUSE; NONHUMAN; PARVOVIRUS; PRIORITY JOURNAL; PROTEIN DOMAIN; VACCINE PRODUCTION; VIRUS CAPSID; VIRUS NEUTRALIZATION; VIRUS PARTICLE; VIRUS PLAQUE; VIRUS RECOMBINANT;

ANIMALS; ANTIBODIES, VIRAL; ANTIGEN PRESENTATION; CAPSID PROTEINS; CELL LINE; DENGUE VIRUS; EPITOPES; GENE ORDER; MICE; MICE, INBRED BALB C; NEUTRALIZATION TESTS; PARVOVIRUS B19, HUMAN; RECOMBINANT PROTEINS; SPODOPTERA;

EID: 33748432831     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/506361     Document Type: Article

References (16)

1. Hombach J, Barrett AD, Cardosa MJ, et al. Review on flavivirus vaccine development. Proceedings of a meeting jointly organised by the World Health Organization and the Thai Ministry of Public Health, 26-27 April 2004, Bangkok, Thailand. Vaccine 2004; 23:2689-95.
2. Pang T. Vaccines for the prevention of neglected diseases-dengue fever. Curr Opin Biotechnol 2003; 14:332-6.
3. Rothman AL. Dengue: defining protective versus pathologic immunity. J Clin Invest 2004; 113:946-51.
4. Miyamura K, Kajigaya S, Momoeda M, Smith-Gill SJ, Young NS. Parvovirus particles as platforms for protein presentation. Proc Natl Acad Sci USA 1994; 91:8507-11.
5. Roehrig JT, Bolin RA, Kelly RG. Monoclonal antibody mapping of the envelope glycoprotein of the dengue 2 virus, Jamaica. Virology 1998; 246:317-28.
6. Se-Thoe SY, Ling AE, Ng MM. Alteration of virus entry mode: a neutralisation mechanism for Dengue-2 virus. J Med Virol 2000; 62:364-76.
7. Seligman SJ, Gould EA. Live flavivirus vaccines: reasons for caution. Lancet 2004; 363:2073-5.
8. Sedlik C, Saron MF, Sarraseca J, Casal I, Leclerc C. Recombinant parvovirus-like particles as an antigen carrier: a novel nonreplicative exogenous antigen to elicit protective antiviral cytotoxic T cells. Proc Natl Acad Sci USA 1997; 94:7503-8.
9. Crill WD, Roehrig JT. Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells. J Virol 2001; 75:7769-73.
10. Kajigaya S, Momoeda M. Human parvovirus B19 epidemiology and clinical manifestations. In: Human parvovirus B19. Anderson LJ, Young NS, eds. Basel, Switzerland: Karger, 1997:120-36.
11. Ballou WR, Reed JL, Noble W, Young NS, Koenig S. Safety and immunogenicity of a recombinant parvovirus B19 vaccine formulated with MF59C.1. J Infect Dis 2003; 187:675-8.
12. Kenney RT, Edelman R. Survey of human-use adjuvants. Expert Rev Vaccines 2003; 2:167-88.
13. Robert Putnak J, Coller BA, Voss G, et al. An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model. Vaccine 2005; 23:4442-52.
14. Guirakhoo F, Pugachev K, Zhang Z, et al. Safety and efficacy of chimeric yellow fever-dengue virus tetravalent vaccine formulations in non-human primates. J Virol 2004; 78:4761-75.
15. Lo-Man R, Rueda P, Sedlik C, Deriaud E, Casal I, Leclerc C. A recombinant virus-like particle system derived from parvovirus as an efficient antigen carrier to elicit a polarized Th1 immune response without adjuvant. Eur J Immunol 1998; 28:1401-7.
16. Sedlik C, Dridi A, Deriaud E, et al. Intranasal delivery of recombinant parvovirus-like particles elicits cytotoxic T-cell and neutralizing antibody responses. J Virol 1999; 73:2739-44.